Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NORTHWEST BIOTHERAPEUTICS INCNWBO · Entity 5982 | Director | May 28, 2018 | May 31, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NORTHWEST BIOTHERAPEUTICS INC
Report date May 28, 2018 · Filed May 31, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase Common Stock, par value $0.001SEC Table II · derivative / convertible security · Conversion / exercise price $0.23 · Expires 2028-05-28 | Direct | 1,715,000 |
Reported balance
After 2018-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-28 · Grant · Acquired 1,715,000 · Balance 1,715,000 F1: These 1,715,000 Options were previously reported and were approved by shareholders at the Special Shareholder Meeting on April 27, 2018. Half of the Options are vested at the time of issuance and half will vest monthly over the course of 24 months from the date of Board approval, subject to acceleration in certain circumstances. F2: The exercise price of the Options is $0.23. |
Filing footnotes · ownership attribution and instrument terms
F1: These 1,715,000 Options were previously reported and were approved by shareholders at the Special Shareholder Meeting on April 27, 2018. Half of the Options are vested at the time of issuance and half will vest monthly over the course of 24 months from the date of Board approval, subject to acceleration in certain circumstances.
F2: The exercise price of the Options is $0.23.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2018 Filed May 31, 2018 01:59 UTC | NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 | GrantOptions to purchase Common Stock, par value $0.001 · Derivative | 1,715,000 | Not disclosed Strike: $0.23 | Not disclosed |
DisclosureSEC source: 0001144204-18-031802 · tv495285_4.xml · derivative · entry 1 BLACK COFER · CIK 0001669037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,715,000 Underlying: Common Stock, par value $0.001 · 1,715,000 shares Expires 2028-05-28 F1 · shares: These 1,715,000 Options were previously reported and were approved by shareholders at the Special Shareholder Meeting on April 27, 2018. Half of the Options are vested at the time of issuance and half will vest monthly over the course of 24 months from the date of Board approval, subject to acceleration in certain circumstances. F2 · price: The exercise price of the Options is $0.23. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.